Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 24
Filtrar
Más filtros

País/Región como asunto
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
J Hepatol ; 78(3): 663-671, 2023 03.
Artículo en Inglés | MEDLINE | ID: mdl-36283499

RESUMEN

Addressing primary care's low confidence in detecting and managing chronic liver disease is becoming increasingly important owing to the escalating prevalence of its common lifestyle-related metabolic risk factors - obesity, physical inactivity, smoking and alcohol consumption. Whilst liver blood testing is frequently carried out in the management of long-term conditions, its interpretation is not typically focused on specific liver disease risk. Educational steps for primary care should outline how liver fibrosis is the flag of pathological concern, encourage use of pragmatic algorithms such as fibrosis-4 index to differentiate between those requiring referral for further fibrosis risk assessment and those who can be managed in the community, and emphasise that isolated minor liver function test abnormalities are unreliable for estimating the risk of fibrosis progression. Measures to increase primary care's interest and engagement should make use of existing frameworks for the management of long-term conditions, so that liver disease is considered alongside other metabolic disorders, including type 2 diabetes, cardiovascular disease, chronic kidney disease etc. Selling points when considering the required investment in developing local fibrosis assessment pathways include reduced repeat testing of minor abnormalities and improved secondary care referrals, plus improvements in the patient's journey through long-term multimorbidity care. A focus on improving chronic liver disease is likely to have wide-ranging benefits across co-existing metabolic disorders, particularly when pathways are aligned with community lifestyle support services. The important message for primary care is to increase the value of existing monitoring rather than to generate more work.


Asunto(s)
Diabetes Mellitus Tipo 2 , Gastroenterología , Humanos , Cirrosis Hepática , Atención Primaria de Salud , Mecanismo de Reembolso
2.
Br J Nutr ; 127(9): 1352-1357, 2022 05 14.
Artículo en Inglés | MEDLINE | ID: mdl-34719409

RESUMEN

In May 2021, the Scientific Advisory Committee on Nutrition (SACN) published a risk assessment on lower carbohydrate diets for adults with type 2 diabetes (T2D)(). The purpose of the report was to review the evidence on 'low'-carbohydrate diets compared with the current UK government advice on carbohydrate intake for adults with T2D. However, since there is no agreed and widely utilised definition of a 'low'-carbohydrate diet, comparisons in the report were between lower and higher carbohydrate diets. SACN's remit is to assess the risks and benefits of nutrients, dietary patterns, food or food components for health by evaluating scientific evidence and to make dietary recommendations for the UK based on its assessment(). SACN has a public health focus and only considers evidence in healthy populations unless specifically requested to do otherwise. Since the Committee does not usually make recommendations relating to clinical conditions, a joint working group (WG) was established in 2017 to consider this issue. The WG comprised members of SACN and members nominated by Diabetes UK, the British Dietetic Association, Royal College of Physicians and Royal College of General Practitioners. Representatives from NHS England and NHS Health Improvement, the National Institute for Health and Care Excellence and devolved health departments were also invited to observe the WG. The WG was jointly chaired by SACN and Diabetes UK.


Asunto(s)
Diabetes Mellitus Tipo 2 , Dietética , Adulto , Humanos , Dieta Baja en Carbohidratos , Carbohidratos , Inglaterra
3.
Lancet ; 391(10125): 1097-1107, 2018 03 17.
Artículo en Inglés | MEDLINE | ID: mdl-29198562

RESUMEN

This report contains new and follow-up metric data relating to the eight main recommendations of the Lancet Standing Commission on Liver Disease in the UK, which aim to reduce the unacceptable harmful consequences of excess alcohol consumption, obesity, and viral hepatitis. For alcohol, we provide data on alcohol dependence, damage to families, and the documented increase in alcohol consumption since removal of the above-inflation alcohol duty escalator. Alcoholic liver disease will shortly overtake ischaemic heart disease with regard to years of working life lost. The rising prevalence of overweight and obesity, affecting more than 60% of adults in the UK, is leading to an increasing liver disease burden. Favourable responses by industry to the UK Government's soft drinks industry levy have been seen, but the government cannot continue to ignore the number of adults being affected by diabetes, hypertension, and liver disease. New direct-acting antiviral drugs for the treatment of chronic hepatitis C virus infection have reduced mortality and the number of patients requiring liver transplantation, but more screening campaigns are needed for identification of infected people in high-risk migrant communities, prisons, and addiction centres. Provision of care continues to be worst in regions with the greatest socioeconomic deprivation, and deficiencies exist in training programmes in hepatology for specialist registrars. Firm guidance is needed for primary care on the use of liver blood tests in detection of early disease and the need for specialist referral. This report also brings together all the evidence on costs to the National Health Service and wider society, in addition to the loss of tax revenue, with alcohol misuse in England and Wales costing £21 billion a year (possibly up to £52 billion) and obesity costing £27 billion a year (treasury estimates are as high as £46 billion). Voluntary restraints by the food and drinks industry have had little effect on disease burden, and concerted regulatory and fiscal action by the UK Government is essential if the scale of the medical problem, with an estimated 63 000 preventable deaths over the next 5 years, is to be addressed.


Asunto(s)
Consumo de Bebidas Alcohólicas/efectos adversos , Costo de Enfermedad , Costos de la Atención en Salud , Hepatitis Viral Humana/complicaciones , Hepatopatías Alcohólicas/epidemiología , Obesidad/complicaciones , Humanos , Hepatopatías Alcohólicas/economía , Hepatopatías Alcohólicas/terapia , Reino Unido/epidemiología
8.
Lancet ; 384(9958): 1953-97, 2014 Nov 29.
Artículo en Inglés | MEDLINE | ID: mdl-25433429
9.
Obes Facts ; 12(1): 40-66, 2019.
Artículo en Inglés | MEDLINE | ID: mdl-30673677

RESUMEN

The first contact for patients with obesity for any medical treatment or other issues is generally with General Practitioners (GPs). Therefore, given the complexity of the disease, continuing GPs' education on obesity management is essential. This article aims to provide obesity management guidelines specifically tailored to GPs, favouring a practical patient-centred approach. The focus is on GP communication and motivational interviewing as well as on therapeutic patient education. The new guidelines highlight the importance of avoiding stigmatization, something frequently seen in different health care settings. In addition, managing the psychological aspects of the disease, such as improving self-esteem, body image and quality of life must not be neglected. Finally, the report considers that achieving maximum weight loss in the shortest possible time is not the key to successful treatment. It suggests that 5-10% weight loss is sufficient to obtain substantial health benefits from decreasing comorbidities. Reducing waist circumference should be considered even more important than weight loss per se, as it is linked to a decrease in visceral fat and associated cardiometabolic risks. Finally, preventing weight regain is the cornerstone of lifelong treatment, for any weight loss techniques used (behavioural or pharmaceutical treatments or bariatric surgery).


Asunto(s)
Manejo de la Obesidad/normas , Obesidad/terapia , Atención Dirigida al Paciente/normas , Guías de Práctica Clínica como Asunto , Atención Primaria de Salud/normas , Adulto , Comorbilidad , Europa (Continente)/epidemiología , Médicos Generales/organización & administración , Médicos Generales/normas , Humanos , Obesidad/epidemiología , Manejo de la Obesidad/métodos , Manejo de la Obesidad/organización & administración , Calidad de Vida , Circunferencia de la Cintura , Pérdida de Peso
10.
Br J Gen Pract ; 58(547): 112-7, 2008 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-18307855

RESUMEN

In view of the limited success rates of all weight-loss strategies to date, this article hypothesises that in situations where previous dieting attempts have failed, better outcomes and health improvements will arise from advocating weight-stability goals. This means the promotion of weight maintenance (to ensure any reduction in weight is maintained) and weight constancy (where steps are taken to maintain existing weight without attempting weight loss), rather than advocating existing 5-10% weight-loss targets for these patients. The majority of approaches to obesity focus on weight reduction despite poor evidence of effectiveness. Primary care remains reluctant to engage in ineffective approaches, yet is well placed to give advice, and would undoubtedly adopt effective obesity-management approaches if they were developed. Despite guidance for overweight or obese people to aim for a 5-10% weight reduction, current trends demonstrate escalation of average weights and obesity. A literature review found little information about evaluation of weight-stability approaches (either weight maintenance or weight constancy), despite theoretical support for them. Yet taking steps to protect weight reduction where it is achieved, and to promote weight constancy (without weight loss) where further dieting is predicted to fail, would have a beneficial effect on preventing further growth of obesity-related morbidity in the population. Some evidence exists to support simple behavioural approaches to improve weight stability, but these measures do not feature in current advice and hence are not widely advocated.


Asunto(s)
Actitud Frente a la Salud , Peso Corporal , Promoción de la Salud , Obesidad/prevención & control , Pérdida de Peso , Adulto , Índice de Masa Corporal , Niño , Ejercicio Físico , Medicina Familiar y Comunitaria , Femenino , Humanos , Masculino , Obesidad/psicología
12.
Br J Gen Pract ; 67(659): 252, 2017 06.
Artículo en Inglés | MEDLINE | ID: mdl-28546393
13.
BMJ ; 355: i5436, 2016 10 11.
Artículo en Inglés | MEDLINE | ID: mdl-27729355
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA